Production (Stage)
Connect Biopharma Holdings Limited
CNTB
$0.9301
-$0.0199-2.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.26% | 48.27% | 48.27% | -8.24% | -1.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 87.87% | 87.87% | -87.87% | -- |
| Total Operating Expenses | -9.39% | -15.06% | -15.06% | -45.54% | -24.28% |
| Operating Income | 9.39% | 20.44% | 20.44% | 117.81% | 24.28% |
| Income Before Tax | -17.95% | 26.80% | 26.80% | 125.35% | 43.03% |
| Income Tax Expenses | 80.00% | 191.07% | 191.07% | -6.25% | -6.25% |
| Earnings from Continuing Operations | -18.16% | 26.41% | 26.41% | 125.10% | 42.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.16% | 26.41% | 26.41% | 125.10% | 42.95% |
| EBIT | 9.39% | 20.44% | 20.44% | 117.81% | 24.28% |
| EBITDA | 9.58% | 20.55% | 20.55% | 119.04% | 24.43% |
| EPS Basic | -17.62% | 26.68% | 26.68% | 125.07% | 42.99% |
| Normalized Basic EPS | -17.40% | 24.34% | 24.34% | 128.10% | 43.05% |
| EPS Diluted | -17.62% | 26.72% | 26.72% | 125.07% | 42.99% |
| Normalized Diluted EPS | -17.40% | 24.34% | 24.34% | 127.93% | 43.05% |
| Average Basic Shares Outstanding | 0.45% | 0.36% | 0.36% | 0.17% | 0.09% |
| Average Diluted Shares Outstanding | 0.45% | 0.36% | 0.36% | 0.91% | 0.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |